Your session is about to expire
← Back to Search
Alpha-1 Adrenergic Receptor Antagonist
Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy
Phase 2
Waitlist Available
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Women 18-80 undergoing outpatient minimally invasive hysterectomy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Summary
This trial is testing if giving a single dose of tamsulosin before surgery can help women who are having a minimally invasive hysterectomy to urinate sooner and leave the hospital faster. Tamsulosin has been studied for its effectiveness in reducing postoperative urinary retention in various surgeries.
Eligible Conditions
- Urinary Retention
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Time to Spontaneous Void
Secondary study objectives
Time to Discharge From the Post-anesthesia Care Unit
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Tamsulosin- intervention groupExperimental Treatment1 Intervention
Group II: Placebo groupPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tamsulosin
2002
Completed Phase 4
~16790
Find a Location
Who is running the clinical trial?
University of ArizonaLead Sponsor
536 Previous Clinical Trials
159,569 Total Patients Enrolled
1 Trials studying Urinary Retention
120 Patients Enrolled for Urinary Retention